2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          As there is significant heterogeneity in the weight loss response to pharmacotherapy, one of the most important clinical questions in obesity medicine is how to predict an individual’s response to pharmacotherapy. The present study examines patterns of weight loss among overweight and obese women who demonstrated early robust response to twice daily exenatide treatment compared to those treated with hypocaloric diet and matched placebo injections.

          Methods

          We randomized 182 women (BMI 25-48 kg/m2) to treatment with exenatide alone or matched placebo injections plus hypocaloric diet. In both treatment groups, women who demonstrated ≥ 5% weight loss at 12 weeks were characterized as high responders and those who lost ≥10% of body weight were classified as super responders. Our primary outcome was long-term change in body weight among early high responders to either treatment. An exploratory metabolomic analysis was also performed.

          Results

          We observed individual variability in weight loss with both exenatide and hypocaloric diet plus placebo injections. There was a trend toward a higher percentage of subjects who achieved ≥ 5% weight loss with exenatide compared to diet (56% of those treated with exenatide, 76% of those treated with diet, p = 0.05) but no significant difference in those who achieved ≥ 10% weight loss (23% of individuals treated with exenatide and 36% of those treated with diet, p = 0.55). In both treatment groups, higher weight loss at 3 months of treatment predicted super responder status (diet p=0.0098, exenatide p=0.0080). Both treatment groups also demonstrated similar peak weight loss during the study period. We observed lower cysteine concentrations in the exenatide responder group (0.81 vs 0.48 p < 0.0001) and a trend toward higher levels of serotonin, aminoisobutyric acid, anandamide, and sarcosine in the exenatide super responder group.

          Conclusion

          In a population of early high responders, longer term weight loss with exenatide treatment is similar to that achieved with a hypocaloric diet.

          Clinical Trial Registration

          www.clinicaltrialsgov, identifier NCT01590433.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: found

          Once-Weekly Semaglutide in Adults with Overweight or Obesity

          Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

            Type 2 diabetes is a chronic disorder that requires lifelong treatment. We aimed to assess whether intensive weight management within routine primary care would achieve remission of type 2 diabetes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Metabolite profiles and the risk of developing diabetes.

              Emerging technologies allow the high-throughput profiling of metabolic status from a blood specimen (metabolomics). We investigated whether metabolite profiles could predict the development of diabetes. Among 2,422 normoglycemic individuals followed for 12 years, 201 developed diabetes. Amino acids, amines and other polar metabolites were profiled in baseline specimens by liquid chromatography-tandem mass spectrometry (LC-MS). Cases and controls were matched for age, body mass index and fasting glucose. Five branched-chain and aromatic amino acids had highly significant associations with future diabetes: isoleucine, leucine, valine, tyrosine and phenylalanine. A combination of three amino acids predicted future diabetes (with a more than fivefold higher risk for individuals in top quartile). The results were replicated in an independent, prospective cohort. These findings underscore the potential key role of amino acid metabolism early in the pathogenesis of diabetes and suggest that amino acid profiles could aid in diabetes risk assessment.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                17 November 2021
                2021
                : 12
                : 742873
                Affiliations
                [1] Beth Israel Deaconess Medical Center , Boston, MA, United States
                Author notes

                Edited by: Luca Busetto, Università degli Studi di Padova, Italy

                Reviewed by: Giulia Quinto, University of Padua, Italy; Mikiko Watanabe, Sapienza University of Rome, Italy

                *Correspondence: Jody Dushay, jdushay@ 123456bidmc.harvard.edu

                This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology

                Article
                10.3389/fendo.2021.742873
                8635796
                69804093-2bbb-45ba-b6e0-a388cc539708
                Copyright © 2021 Rodgers, Migdal, Rodríguez, Chen, Nath, Gerszten, Kasid, Toschi, Tripaldi, Heineman, Phan, Ngo, Maratos-Flier and Dushay

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 16 July 2021
                : 18 October 2021
                Page count
                Figures: 5, Tables: 2, Equations: 0, References: 33, Pages: 11, Words: 6782
                Funding
                Funded by: AstraZeneca Pharma Poland , doi 10.13039/501100014091;
                Categories
                Endocrinology
                Clinical Trial

                Endocrinology & Diabetes
                overweight,obesity,weight loss,exenatide,hypocaloric diet
                Endocrinology & Diabetes
                overweight, obesity, weight loss, exenatide, hypocaloric diet

                Comments

                Comment on this article